Literature DB >> 22561841

Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.

Yoshito Hirata1, Koichiro Akakura, Celestia S Higano, Nicholas Bruchovsky, Kazuyuki Aihara.   

Abstract

If a mathematical model is to be used in the diagnosis, treatment, or prognosis of a disease, it must describe the inherent quantitative dynamics of the state. An ideal candidate disease is prostate cancer owing to the fact that it is characterized by an excellent biomarker, prostate-specific antigen (PSA), and also by a predictable response to treatment in the form of androgen suppression therapy. Despite a high initial response rate, the cancer will often relapse to a state of androgen independence which no longer responds to manipulations of the hormonal environment. In this paper, we present relevant background information and a quantitative mathematical model that potentially can be used in the optimal management of patients to cope with biochemical relapse as indicated by a rising PSA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561841      PMCID: PMC3612008          DOI: 10.1093/jmcb/mjs020

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  28 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.

Authors:  Trachette L Jackson
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

3.  Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.

Authors:  Celestia Higano; Andrew Shields; Nathanael Wood; Judy Brown; Cathy Tangen
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

4.  Intermittent endocrine therapy for advanced prostate cancer.

Authors:  L H Klotz; H W Herr; M J Morse; W F Whitmore
Journal:  Cancer       Date:  1986-12-01       Impact factor: 6.860

5.  Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.

Authors:  John M Kokontis; Stephen Hsu; Chih-pin Chuu; Mai Dang; Junichi Fukuchi; Richard A Hiipakka; Shutsung Liao
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

6.  Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.

Authors:  Nicholas Bruchovsky; Laurence Klotz; Juanita Crook; Shawn Malone; Charles Ludgate; W James Morris; Martin E Gleave; S Larry Goldenberg
Journal:  Cancer       Date:  2006-07-15       Impact factor: 6.860

7.  Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.

Authors:  Chih-pin Chuu; Richard A Hiipakka; Junichi Fukuchi; John M Kokontis; Shutsung Liao
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

Review 8.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

9.  Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.

Authors:  K Akakura; N Bruchovsky; S L Goldenberg; P S Rennie; A R Buckley; L D Sullivan
Journal:  Cancer       Date:  1993-05-01       Impact factor: 6.860

10.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

Authors:  J M Kokontis; N Hay; S Liao
Journal:  Mol Endocrinol       Date:  1998-07
View more
  8 in total

1.  A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.

Authors:  Marisa C Eisenberg; Harsh V Jain
Journal:  J Theor Biol       Date:  2017-07-19       Impact factor: 2.691

2.  Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.

Authors:  Yoshito Hirata; Kai Morino; Koichiro Akakura; Celestia S Higano; Kazuyuki Aihara
Journal:  Sci Rep       Date:  2018-02-08       Impact factor: 4.379

3.  PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer.

Authors:  Xingcheng Lin; Susmita Roy; Mohit Kumar Jolly; Federico Bocci; Nicholas P Schafer; Min-Yeh Tsai; Yihong Chen; Yanan He; Alexander Grishaev; Keith Weninger; John Orban; Prakash Kulkarni; Govindan Rangarajan; Herbert Levine; José N Onuchic
Journal:  J Mol Biol       Date:  2018-06-05       Impact factor: 5.469

4.  Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy.

Authors:  Yoshito Hirata; Kai Morino; Koichiro Akakura; Celestia S Higano; Nicholas Bruchovsky; Teresa Gambol; Susan Hall; Gouhei Tanaka; Kazuyuki Aihara
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

5.  Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

Authors:  J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-30

6.  Predicting disease progression from short biomarker series using expert advice algorithm.

Authors:  Kai Morino; Yoshito Hirata; Ryota Tomioka; Hisashi Kashima; Kenji Yamanishi; Norihiro Hayashi; Shin Egawa; Kazuyuki Aihara
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

7.  Massive computational acceleration by using neural networks to emulate mechanism-based biological models.

Authors:  Shangying Wang; Kai Fan; Nan Luo; Yangxiaolu Cao; Feilun Wu; Carolyn Zhang; Katherine A Heller; Lingchong You
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

8.  Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.

Authors:  Arturo Araujo; Leah M Cook; Jeremy S Frieling; Winston Tan; John A Copland; Manish Kohli; Shilpa Gupta; Jasreman Dhillon; Julio Pow-Sang; Conor C Lynch; David Basanta
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.